NY-ESO-1抗原的主要组织相容性复合体(MHC)I类加工过程受Rpn10和Rpn13蛋白以及非赖氨酸泛素化后的免疫蛋白酶体调控。
Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination.
作者信息
Golnik Richard, Lehmann Andrea, Kloetzel Peter-Michael, Ebstein Frédéric
机构信息
From the Institute for Biochemistry, Charité-Universitätsmedizin Berlin, Charité Platz 1/Virchowweg 6, 10117 Berlin, Germany.
From the Institute for Biochemistry, Charité-Universitätsmedizin Berlin, Charité Platz 1/Virchowweg 6, 10117 Berlin, Germany
出版信息
J Biol Chem. 2016 Apr 15;291(16):8805-15. doi: 10.1074/jbc.M115.705178. Epub 2016 Feb 22.
The supply of MHC class I-restricted peptides is primarily ensured by the degradation of intracellular proteins via the ubiquitin-proteasome system. Depending on the target and the enzymes involved, ubiquitination is a process that may dramatically vary in terms of linkages, length, and attachment sites. Here we identified the unique lysine residue at position 124 of the NY-ESO-1 cancer/testis antigen as the acceptor site for the formation of canonical Lys-48-linkages. Interestingly, a lysine-less form of NY-ESO-1 was as efficient as its wild-type counterpart in supplying the HLA-A*0201-restricted NY-ESO-1157-165 antigenic peptide. In fact, we show that the regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites. In summary, our data underscore the significance of atypical ubiquitination in the modulation of MHC class I antigen processing.
主要组织相容性复合体(MHC)I类限制性肽的供应主要通过泛素 - 蛋白酶体系统对细胞内蛋白质的降解来确保。根据靶标和所涉及的酶,泛素化是一个在连接方式、长度和附着位点方面可能有显著差异的过程。在这里,我们确定了NY-ESO-1癌胚抗原第124位独特的赖氨酸残基是形成典型的赖氨酸48连接的接受位点。有趣的是,一种无赖氨酸形式的NY-ESO-1在提供HLA-A*0201限制性NY-ESO-1157-165抗原肽方面与其野生型对应物一样有效。事实上,我们表明泛素受体Rpn10和Rpn13以及标准蛋白酶体和免疫蛋白酶体对NY-ESO-1加工的调节是由非赖氨酸位点上的非典型泛素化控制的。总之,我们的数据强调了非典型泛素化在调节MHC I类抗原加工中的重要性。
相似文献
Beijing Da Xue Xue Bao Yi Xue Ban. 2005-12-18
Cancer Res. 2005-11-1
引用本文的文献
Front Immunol. 2025-8-1
Front Mol Biosci. 2024-2-13
Methods Mol Biol. 2023
Biomolecules. 2021-1-5
Nat Chem Biol. 2020-9-17
本文引用的文献
Cell Rep. 2014-6-12
Trends Immunol. 2014-4
Biochim Biophys Acta. 2014-1
Annu Rev Biochem. 2012-4-10
Cell Mol Life Sci. 2011-3-17
Cell Mol Life Sci. 2011-3-9